Many experts and women living with the disease say the name polycystic ovary syndrome is reductive and misleading More than one in 10 women of reproductive age have a hormonal disorder which can have wide-ranging health effects, including on metabolism, skin, mental health and the reproductive and cardiovascular systems. Despite these diverse symptoms, the condition is known as polycystic ovary syndrome, or PCOS. It is a name many experts and those living with the disease says is reductive and misleading, prompting a global initiative working to formally rename PCOS to something that more accurately reflects the disease. Continue reading...

Nietzsche condemned anyone offering ‘answers’ or ‘solace’ – but engaging with nihilism can teach us to face the discomfort of a potentially meaningless existence Get our weekend culture and lifestyle email A trick I developed in the late stages of my first pregnancy to forestall inquiries, concern, recommendations and advice about having a baby was to refer to her impending birth as “the apocalypse”. “I don’t know,” I’d shrug. “We’ll see what things look like after the apocalypse.” Continue reading...

rosnita mahmud/iStock via Getty Images Approaching CoreWeave's Q4 Earnings I haven't written about CoreWeave, Inc. ( CRWV ) stock as a standalone ticker - only as a comparison to its direct peer, Nebius Group N.V. ( NBIS ). So far, I've compared CRWV and NBIS twice, always favoring the latter thanks to its seemingly better-developed software layer on top of just leasing out GPUs, its better business diversification (as they hold stakes in other tech companies in non-neocloud niches), and an overall stronger balance sheet with a limited debt load. NBIS has already reported its Q4 results , and CoreWeave is about to report its Q4 results in a few days, on February 26th . I think it's time for me to update my coverage on CRWV, preview its upcoming earnings, and dedicate my research to this standalone ticker. From what I'm seeing, the company is very likely to beat earnings, or at least guide in a bullish way for next year, thanks to abandoning its reliance on one dominant supplier and launching its CoreWeave ARENA in February 2026, which should increase customer stickiness in the medium term. Over the past 3 months, CRWV beat the revenue consensus quite meaningfully, and I see a similar thing for Q4. Technicals suggest that if CRWV manages to rise on the Q4 earnings catalyst, we might see a strong rally, so I'm upgrading my rating from "Hold" to "Buy" ahead of the print. Why Do I Think So? The CRWV has declined by over 52% since June 20th, 2025, and it's currently consolidating close to its strong support levels. We can argue about the reasons, but among the main ones I see are the debt load and heavy concentration with a single infrastructure partner. Plus, a lot of people feared the firm's assets' potential obsolescence in the upcoming years, as CRWV was viewed as just a GPU REIT, which carries assets that can get outdated as AI innovation rolls. However, we see that the situation has been changing for the better lately. Their signed contracts were up by 120 MW QoQ i...

Key PointsSIL and SGDM both target precious metals miners, but SIL focuses on silver while SGDM is tilted toward gold.

In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Shelby Knowles | Bloomberg | Getty Images Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug. Patients can use one pen to take four weekly doses of Zepbound. Currently, patients on the treatment use a different single-dose autoinjector device each week. Lilly also offers single-dose vials of Zepbound, which requires users to draw the medication into a syringe and inject themselves. The announcement comes as Lilly works to sustain the early success of Zepbound, which has exploded in demand since it first entered the market in late 2023. LillyDirect has been key to Zepbound's growth, and rolling out a new form of the drug on the platform could attract even more patients. The torrid growth of Zepbound has helped Eli Lilly seize a majority share of the weight-loss drug market from rival Novo Nordisk. In the company's fourth quarter, Zepbound brought in $4.2 billion in U.S. revenue, a 122% spike from the previous year. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro. "As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medici...

Institutions have not been fazed by Bitcoin’s recent sell-off, Coinbase (NASDAQ:COIN) Head of Institutional Strategy John D’Agostino says. D’Agostino on told CNBC on Tuesday that he recently surveyed 130 institutional investors across Hong Kong and the United Arab Emirates, who...

Recently, Zacks.com users have been paying close attention to Amazon (AMZN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Amazon.com, Inc. (AMZN) is a Trending Stock Yahoo Finance

JD.com (JD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Recently, Zacks.com users have been paying close attention to Broadcom Inc. (AVGO). This makes it worthwhile to examine what the stock has in store.

Broadcom Inc. (AVGO) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance

Dan Loeb’s new stakes in Chipotle, Spotify, and Alibaba are a concentrated bet that markets have overshot on fear in three still‑profitable growth franchises, each with clear multi‑year earnings drivers.

In this article STLA Follow your favorite stocks CREATE FREE ACCOUNT 2026 Jeep Cherokee Michael Wayland / CNBC LOS ANGELES – Stellantis is counting on the return of the Jeep Cherokee to help lead a U.S. turnaround for the SUV brand and embattled automaker. The Cherokee returns after a three-year hiatus, rejoining the compact and midsize vehicle markets, which represent the largest segments in the U.S. It also marks Jeep's first traditional hybrid model and its most fuel-efficient, gas-powered vehicle ever in the U.S. "This is a critical vehicle for us," Richard Cox, Jeep senior vice president of brand operations, told CNBC during a media event for the 2026 Cherokee. "I think this expands our reach with this level of powertrain, with this level of fuel efficiency and capability." The vehicle is currently arriving in U.S. dealerships as arguably the most important U.S. launch for the automaker this year. Stellantis is attempting to regain market share after significant losses in recent years. The automaker has set a target to increase retail sales by roughly 25% in 2026 to 1.15 million vehicles, driven by updated and new models as well as pricing and product realignments to move vehicles off dealer lots. "It's a huge part of our growth," Cox said regarding the new Cherokee. "It positions us well in '26." The interior of the 2026 Jeep Cherokee Overland. Stellantis Last year, Jeep narrowly reported its first annual sales increase – up less than 1% – since 2018, when the brand achieved sales of more than 973,200 units. That compares with sales of 593,401 Jeeps in 2025, a 39% decline over the seven-year period. The 1% annual sales growth for Jeep wasn't enough to lift Stellantis' overall U.S. sales into the black for the year, though. The parent company reported a 3% decline in U.S. sales in 2025 – marking its seventh consecutive fall amid a failed push into all-electric vehicles and significant cost cutting and price increases under former CEO Carlos Tavares . Sean Hogan...

Recently, Zacks.com users have been paying close attention to Oracle (ORCL). This makes it worthwhile to examine what the stock has in store.

Oracle Corporation (ORCL) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance Singapore

Oracle Corporation (ORCL) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance

Philip Hoeppli/iStock via Getty Images Introduction When we talk about Medical Properties Trust ( MPT ), discussions tend to become heated very quickly. I can't say that I am not contributing to this sentiment. Then again, I feel that there is too much superficial analysis going on regarding MPT. Some investors are angry (and rightfully so) that the company's stock has cratered in recent years. Part of which can be blamed on management and their equity investments in (bad) tenants. From +/- $24 back in 2022 all the way to $3.73 when I started covering this stock. No wonder why investors are upset. But this is also the time to keep your emotions in check. Going against the market when bearish sentiment is stronger than the fundamentals warrant is a lucrative way to make money. Analyst first article on MPT (Dec. 2024) But I have to be fair: I made a contrarian move too fast regarding Alexandria Real Estate ( ARE ). Timing the market is - as we all know - impossible, but I have learned to wait and see for a bit longer before capitalizing on (irrational) market sentiment. Even though I believe that my ARE investment will play out according to plan, it will take a few more years than anticipated. But that's for a future article. Some investors will never love Medical Properties Trust again, especially those that invested around the $20 mark. Resentment and anger over what happened to them is probably the root cause behind the overall sentiment towards the stock. But that's not something I really care about (other than the fact that I want people to succeed in investing) when I write my articles. Anger, disbelief, fear, or euphoria are best left out of your investing journey. Especially when you invest to achieve great returns, right? You should hate emotions and love fundamental analysis. Keep your eyes on the ball. A lot has happened in between 2022 and Q4 2025. That's why I've written a lot of articles on MPT in the past 18 months or so. The good thing is that Q4 2025 ...

Getty Images I think it's fair for me to say that investors in Astera Labs, Inc. ( ALAB ) are likely shocked to find out that the stock is down almost 60% from its peak in September 2025, before buyers came in to help stem a further slide towards even more painful lows. Well, it's pretty baffling because the AI infrastructure outlay has gone further up, almost reaching the 700 billion dollar mark for 2026. Yet you wouldn't have been able to tell from ALAB's hammering, as if investors don't seem to be convinced about its ability to benefit from this AI boom. So what is going on that the market has simply turned its back on what should have been a clear beneficiary as the scale-up and scale-out themes stretch out through the rest of the decade? Management made sure to remind us that Astera Labs remains incredibly well primed to benefit from the more complex solutions requirements in the emerging AI rack-level setups panning out: During the quarter, we enjoyed revenue growth from our Scorpio, Aries, and Taurus product lines, supporting both scale-up and scale-out PCIe and Ethernet connectivity for a wide range of AI rack-level configurations. Scorpio P-Series demand for PCIe Gen 6 switching applications was robust during Q4. - ALAB Q4 2025 earnings call. What are investors truly worried about? Is Astera Labs profitable? Checked. Is the company considered interoperable across multiple platform ecosystems and able to meet the needs of various requirements from different hyperscalers when called upon? Checked. Has the company been able to expand its revenue exposure beyond its core customer, Amazon.com, Inc. ( AMZN )? Checked. Note that management indicated clearly that ALAB is "commencing shipments into at least 2 additional major hyperscalers on their next-generation AI platforms." Therefore, I do find it somewhat perplexing in trying to assess what is keeping the market so concerned that I could have been missing. Amid all this furor hanging over the bullish narrative ...

LAVAL, Quebec, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, announces it will release its financial results for the fourth quarter of 2025 after market closes on March 4, 2026. Savaria’s management will hold an investor conference call and webcast at 8:30 a.m. Eastern Standard Time (EST) on Thursday, March 5, 2026. Investors and members of the media are invited to participate on a listen-only basis.

LAVAL, Québec, 23 févr. 2026 (GLOBE NEWSWIRE) -- Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, annonce qu’elle divulguera ses résultats financiers pour le quatrième trimestre 2025 le 4 mars 2026 après la fermeture des marchés. Les membres de la direction de Savaria tiendront une conférence téléphonique et une webdiffusion à l’intention des investisseurs à 8 h 30, heure normale de l’Est (HNE), le jeudi 5 mars 2026. Les investisseurs et les membres des médias sont invités à participer en mode audio seulement.

Avalara, Inc., the agentic tax and compliance leader, today announced the availability of Avalara AvaTax in the Microsoft Marketplace, the unified online destination for customers to buy trusted cloud solutions, AI apps, and agents to meet their business needs. Avalara AvaTax customers can now discover and deploy trusted solutions through the Microsoft Marketplace, with smooth integration and streamlined management across Microsoft Azure and other Microsoft products.

HERNDON, Va., February 23, 2026--Microsoft has approved Everfox's Trusted Thin Client product as the first Cross Domain secure access solution for Microsoft Azure clouds.

Sela and 2bcloud announced their merger, forming one of the region's largest multi-cloud engineering organizations.

Electrical equipment manufacturers are racing to meet demand for the crucial parts that connect data centers to power. For the few companies cornering that market, that’s meant record orders and bloated backlogs. Vertiv Holdings Co. , Eaton Corp. and GE Vernova Inc. all saw orders jump in the final quarter of last year, something they attribute to ballooning data center demand — which isn’t showing any signs of letting up. The four biggest hyperscalers plan to spend a combined $650 billion on data centers and all of the electrical equipment and gear that powers them this year alone — a mind-boggling forecast that could signal even better quarters ahead for the companies on the other end of that money. Hyperscale and colocation data centers were the primary drivers of a 252% jump in Vertiv’s fourth-quarter orders. Data centers currently account for 80% to 85% of the company’s total revenue, Chief Financial Officer Craig Chamberlin said in an interview. “It’s a large portion of what we go and deliver on, and it’s a large portion of our growth.” Peers share in the spoils. Eaton’s Electrical Americas data center orders rose 200% last quarter, while GE Vernova’s jumped 65% . “We’re at the point where suppliers hold a majority of the power, pretty much all their production stocks are getting filled out,” said Wood Mackenzie analyst Benjamin Boucher. “The purchasers or the buyers hold very little power, and it’s all on the supplier side, which is a big turnaround from what we were seeing four, five, six years ago, kind of the post-pandemic days, when demand was kind of muted.” That demand is set to carry electric equipment manufacturers through this year. Vertiv expects its backlog to meet more than 100% of its 2026 sales guidance, while French equipment provider Legrand SA expects to meet the top end of its 2030 guidance range as data center sales have tripled since 2020. “If you look at the last several years, generally the backlog at the end of the year was worth 65% to...

Skorppio, a new self-serve platform for on-premise high-performance computer rentals, launches today with a fleet of workload-qualified, enterprise-grade systems available for delivery nationwide. The platform serves AI startups, ML developers, VFX studios, simulation teams, and research organizations that need bare-metal compute on-premise, without ownership costs, cloud lock-in, or long-term contracts.

Getty Images I think it's fair for me to say that investors in Astera Labs, Inc. ( ALAB ) are likely shocked to find out that the stock is down almost 60% from its peak in September 2025, before buyers came in to help stem a further slide towards even more painful lows. Well, it's pretty baffling because the AI infrastructure outlay has gone further up, almost reaching the 700 billion dollar mark for 2026. Yet you wouldn't have been able to tell from ALAB's hammering, as if investors don't seem to be convinced about its ability to benefit from this AI boom. So what is going on that the market has simply turned its back on what should have been a clear beneficiary as the scale-up and scale-out themes stretch out through the rest of the decade? Management made sure to remind us that Astera Labs remains incredibly well primed to benefit from the more complex solutions requirements in the emerging AI rack-level setups panning out: During the quarter, we enjoyed revenue growth from our Scorpio, Aries, and Taurus product lines, supporting both scale-up and scale-out PCIe and Ethernet connectivity for a wide range of AI rack-level configurations. Scorpio P-Series demand for PCIe Gen 6 switching applications was robust during Q4. - ALAB Q4 2025 earnings call. What are investors truly worried about? Is Astera Labs profitable? Checked. Is the company considered interoperable across multiple platform ecosystems and able to meet the needs of various requirements from different hyperscalers when called upon? Checked. Has the company been able to expand its revenue exposure beyond its core customer, Amazon.com, Inc. ( AMZN )? Checked. Note that management indicated clearly that ALAB is "commencing shipments into at least 2 additional major hyperscalers on their next-generation AI platforms." Therefore, I do find it somewhat perplexing in trying to assess what is keeping the market so concerned that I could have been missing. Amid all this furor hanging over the bullish narrative ...

Generate Biomedicines Inc. , a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the sector picks up sharply. The Somerville, Massachusetts-based drug developer plans to market 25 million shares for $15 to $17 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of that range, Generate Biomedicines would have a market value of $2.2 billion based on the outstanding shares listed in its filing. The company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume. First-time share sales for firms including Aktis Oncology Inc. and Veradermics Inc. since the start of the year have raised $1.4 billion , surpassing the $915 million raised in the same period in 2025, data compiled by Bloomberg show. Generate is developing medicine for people with severe asthma and chronic obstructive pulmonary disease (COPD), the filing shows. The company expects late-stage trials for severe asthma to be fully enrolled later next year or in the first half of 2028. It expects early-stage data from a COPD study this year, the filing shows. The firm raised $273 million in a Series C financing in 2023 which attracted investors including Amgen Inc. , Nvidia Corp. ’s venture capital arm, MAPS Capital ( Mirae Asset Group ) and Pictet Alternative Advisors . It has also collected $110 million in payments from collaboration agreements with Novartis AG and Amgen. For the latest news on equity capital markets activity in the US, Canada and Latin America, follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . Generate had a net loss of $223 million last year, higher than the net loss of $181 million it reported in 2024, according to its filing. Board chair Noubar Afeyan , who ...

Nvidia Stock Stalls, But JPMorgan Sees Another Beat Ahead - NVIDIA (NASDAQ:NVDA) Benzinga

Nvidia Stock Is Stuck, But JPMorgan Anticipates Another 'Beat-And-Raise' Benzinga

财联社2月23日讯（记者 卢阿峰） 全球基因测序产业竞争格局重塑之际， 华大智造 （688114.SH）再度对其全球业务布局及商业模式进行优化升级。 公司今日晚间发布公告，全资子公司MGI R&D HK与Swiss Rockets签署 了《股份购买协议》，拟将MGI R&D HK剥离相关资产及负债后的全资子公司 CGI的100%股权以约5000万美元的对价出售给Swiss Rockets。并同步修订了去年签订的CoolMPS测序技术授权协议，在既有合作框架上引入StandardMPS测序技术授权，进一步深化了与Swiss Rockets的战略协同。 此次交易是双方自去年达成的首次技术授权合作的延续。2025年10月，华大智造通过旗下MGI US LLC及CGI与Swiss Rockets签署CoolMPS测序技术授权协议，将相关专利、技术秘密及商标在亚太及大中华区以外区域授予对方独占许可。这一安排被业内视为公司在复杂国际环境下，通过“技术出海”替代“资产出海”的关键落子。 彼时合作的核心在于CoolMPS技术，其作为华大智造差异化测序路线的重要组成部分，配套通用测序技术（包括stLFR、cLFR等）一并授权，由Swiss Rockets负责在欧美市场推进商业化落地。根据原协议，公司可获得2000万美元首付款、2000万美元里程碑付款，并基于许可产品净销售额按阶梯比例收取特许权使用费，形成“前端回款+后端分成”的收益结构。 本次公告显示，双方合作进一步升级。一方面，华大智造拟将剥离相关资产及负债后的CGI的100%股权出售给Swiss Rockets，实现北美核心运营主体的“出表”；另一方面，通过《授权许可协议修正案》，新增StandardMPS测序技术在美国及加拿大区域的独占授权。 从交易结构看，此次调整呈现出更为清晰的战略导向：通过股权剥离降低直接经营与合规风险，同时以多技术平台授权锁定长期现金流，推动收入结构由一次性设备销售向持续性技术许可转型。 公告披露，新增授权后，Swiss Rockets未来销售StandardMPS相关产品同样需向公司支付许可费用，分成机制与原CoolMPS协议保持一致。在全部授权期内，华大智造预计可获得不低于1.2亿美元收入，其中包括已收取的2000万美元首付款、2000万美元里程碑付款，以及基于销售额的阶梯式特许权使用费。本次交易相...